STING (Study of Immunotherapy in Newly Diagnosed Glioblastoma): A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy

You are here

Glioblastoma multiforme (GBM) is the most common and fast growing type of brain tumor. The study will compare overall survival and progression-free survival in patients when treated with the ICT-107 vaccine compared to the control.

Contact Dr. Pannullo: 212-746-2438